As part of a $3 billion, multi-state settlement, GlaxoSmithKline will pay New Jersey $22.1 million.
The deal resolves allegations against the company that it engaged in off-labeling marketing of some of its drugs, underpaid Medicaid rebates and oversold the benefits of the diabetes drug Avandia.
N.J. Attorney General Jeffrey Chiesa announced the Garden State’s share of the settlement today. The settlement as a whole includes $2 billion in repayment and a $1 billion fine.
GSK will also plead guilty to charges it violated the federal Food, Drug, and Cosmetic Act.